In patients with coronary artery disease carrying the genetic variant associated with a loss of function of the CYP2C19 enzyme, the risk for stent thrombosis is 3–6 times higher with clopidogrel treatment [10–12]. This evidence concerns the gene CYP2C19 and coronary artery disorder.